Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
7 hedge funds and large institutions have $385K invested in Avenue Therapeutics, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
13% less funds holding
Funds holding: 8 → 7 (-1)
22% less capital invested
Capital invested by funds: $492K → $385K (-$107K)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$284K |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$83.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$3.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.75K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$8 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$286K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$157K |
| 3 |
MAWA
Moss Adams Wealth Advisors
Seattle,
Washington
|
-$27.4K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$124 |
| 5 |
JP Morgan Chase
New York
|
-$3 |
ATXI Hedge Fund Activity: Q4 2024 in Review
7 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q4 2024, worth a combined $385K — down 22% from $492K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ATXI and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $284K. The largest seller was Armistice Capital, exiting entirely with an estimated $286K sold.
- 7 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q4 2024, down from 8 in Q3 2024.
- Funds reported $385K of Avenue Therapeutics, Inc. Common Stock stock for Q4 2024, down 22% quarter-over-quarter.
- 3 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q4 2024 and 4 closed out, a net change of -1 holder.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q4 2024 was Ikarian Capital, an estimated $284K added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q4 2024 was Armistice Capital, an estimated $286K sold.
Based on aggregated 13F filings for Q4 2024.